With Low Percentage Of R&D Funding Going Toward NTDs, Some Pharmaceutical Companies Focus On Partnerships, Collaboration
The Guardian: Is it fair to accuse the pharma industry of neglecting tropical diseases?
“…Currently the biggest impetus for dealing with NTDs seems to come from partnerships. … There is some evidence to suggest the pharma industry uses partnerships to absolve itself of responsibility. Major companies are closing down their NTD R&D operations while opening up their compound libraries to partnerships, such as Novartis to the TB Alliance. … The solution for NTD drug R&D may not be partnerships alone, but must include cross-sector collaboration…” (Smedley, 10/15).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.